Article | July 1, 2020

The Time Is Now For Transformation In Clinical Data Collection

Source: Oracle Health Sciences

By Jim Streeter, global vice president life sciences product strategy, Oracle


When the COVID-19 pandemic began, many clinical trial teams were forced to quickly find remote methods for collecting data and conducting visits so they could keep patients safe and enrolled in trials that were already underway. This swift transition to virtual clinical trials demonstrated that these approaches are not only possible but can bring real benefits to research studies. It also showed that many of the necessary technologies are mature enough to support these approaches in a practical way.

Importantly, the pandemic also forced pharmaceutical companies, which are understandably careful about making changes that might affect drug approval or increase cost, to look beyond the risks and embrace these new technologies. Regulatory agencies are also now more accepting of changes to how clinical trials have always been done. Together, this creates a climate that is ideal for examining the best way forward for virtual clinical trials and new types of data collection.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader